Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital and Alfa eCare in connection with their strategic acquisition of Clinicbuddy
Mandate

Vinge has advised Main Capital and Alfa eCare in connection with their strategic acquisition of Clinicbuddy

June 22, 2021 Employment and Benefits M&A IT, Telecommunications and Outsourcing Commercial Agreements

The Alfa eCare group is a recognized eHealth software company, providing solutions to both public and private healthcare providers throughout Sweden.

Clinicbuddy provides various software solutions for care planning and digitization within healthcare, such as digital medical records and booking systems. The company’s products contribute to safe record keeping for care providers and more efficient and flexible systems for different types of clinics.

Vinge’s team consisted of Filip Öhrner, Kristina Ekberg and Eléonore Friberg (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (GDPR/IT), Rebecka Weitzberg (IP), Lisa Hörnqvist (Agreements) and Sara Dahlros Sköld (VDR).

Related

Vinge has advised Bolero in connection with sale of shares in Ambea AB (publ)

 Vinge has advised Bolero Holdings S.à r.l. in connection with the sale of shares in Ambea AB (publ) through an accelerated bookbuilding process carried out on 1 December 2025.
December 02, 2025

Vinge advises on the sale of Segers Fabriker

 Vinge has advised the sellers in connection with the sale of Segers Fabriker AB to Norrstigen. Segers is a family-owned company in Borås with operations in Sweden, Estonia, and Ukraine, which has developed and sold workwear for hotels, restaurants, and healthcare since 1943.
December 02, 2025

Vinge has advised Intea Fastigheter in connection with a directed share issue of approximately SEK 500 million

 Vinge has advised the property company Intea Fastigheter AB (publ) in connection with a directed share issue of shares of series D through which the company raises proceeds of approximately SEK 500 million before transaction costs. A part of the share issue is subject to subsequent approval at an extraordinary general meeting.
December 01, 2025